Physician profile
James E Thompson
NPI 1023403524
$807.98
in general payments reported to CMS, 2019-2025
11 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.65 · 2022: $103 · 2023: $232 · 2024: $252 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $272.76 | 2021-2025 | Xcopri |
| Ucb, INC. | $228.62 | 2022-2025 | Briviact |
| Acadia Pharmaceuticals INC | $61.94 | 2023-2025 | Daybue |
| Pyros Pharmaceuticals, INC. | $54.04 | 2024 | Vigpoder |
| Piramal Critical Care | $49.31 | 2024-2025 | |
| Immedica Pharma US, INC. | $31.27 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $27.22 | 2023 | Fycompa |
| Neurelis, INC. | $24.47 | 2024 | Valtoco |
| Orchard Therapeutics North America | $23.24 | 2025 | Lenmeldy |
| Ptc Therapeutics, INC. | $20.06 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.